Marcio Andrade Campos

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML

Andrew M. Brunner, Yiwen Liu, Jacqueline Suen Garcia, Lourdes Mendez et autres

Pre-mRNA splicing gene mutations are common in MDS and CMML and induce R-loops which trigger ATR activation. We studied ceralasertib, an orally bioavailable ATR inhibitor, in adult patients with R/R MDS or CMML in a phase Ib/II study including a safety run-in …

us, es, gb (code pays fourni par la source)

Posttransplant Cyclophosphamide-Based Transplantation from Haploidentical Donors Has Similar Outcomes As Unrelated Donor Transplantation in Myelofibrosis: A Center for International BMT Research (CIBMTR) Study

Tania Jain, Noel Estrada‐Merly, Soyoung Kim, María Queralt Salas et autres

Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas

Luís Colomo, Ivonne Vázquez, Natalia Papaleo, Marta Salido et autres

Introduction: MYC rearrangements (MYCr) occur in 5 to 15% of diffuse large B-cell lymphomas (DLBCL) and 20 to 35% of high-grade B-cell lymphoma, NOS (HGBL-NOS), are a defining criterion of the category HGBL with rearrangements of MYC and/or BCL2/BCL6 (HGBL, with MYCr …

es (code pays fourni par la source)

High Diagnostic Utility of Flow Cytometry Based Peripheral Blood Monocyte Subset Analysis, CD56 and CD2 Expression in Chronic Myelomonocytic Leukemia (CMML)

Xavier Calvo, Ivonne Párraga, Nieves García-Gisbert, Lourdes Florensa et autres

INTRODUCTION The diagnosis of CMML according to WHO 2017 requires the presence of ≥1x109/L and ≥10% of monocytes in peripheral blood (PB). Establishing an accurate diagnostic is difficult since many clinical situations present persistent monocytosis. The presence of dysplasia is frequent but …

es (code pays fourni par la source)

Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution

María Queralt Salas, Santiago Mercadal, Eva Domingo‐Doménech, Ana Carla Oliveira et autres

The discriminative power of International Prognostic Index (IPI) in diffuse large B-cell lymphoma (DLBCL) decreased with the addition of rituximab to chemotherapy. The National Comprehensive Cancer Network (NCCN)-IPI and the Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO)-IPI were …

es (code pays fourni par la source)